Influence of synaptic serotonin level on [18F]altanserin binding to 5HT2 receptors in man

The feasibility of in vivo serotonin 5HT(2) receptor binding measurement using [18F]altanserin as a radioligand has been well established. In this study, the postsynaptic receptor binding potential of this ligand was examined as a possible indicator of synaptic serotonin content after pharmacological challenge. Studies were performed in 11 subjects with a history of recurrent major depression. Six of them received serotonergic antidepressive treatment at the time of the experiment, the other five patients were untreated. Two PET measurements were carried out in each subject within 2 or 3 days. Before one of the measurements, 25 mg of the serotonin re-uptake inhibitor clomipramine were given intravenously, the other measurement was done without pharmacological challenge. The data were analyzed using non-linear least-square regression and Logan's graphical method. In the whole group of subjects, binding potential and distribution volume of altanserin decreased following clomipramine challenge. The decrease was between 14 (P=0.03) and 23% (P=0.004). This effect was mainly seen in subjects not on antidepressive medication. Clomipramine challenge probably increased the synaptic serotonin level, which competed with altanserin leading to the lowered binding potential. The paradigm might, thus, be useful to estimate serotonin release in vivo. Pretreatment with serotonergic antidepressants reduces the effect of clomipramine.

[1]  Richard S. J. Frackowiak,et al.  Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age. , 1990, Brain : a journal of neurology.

[2]  J J Grome,et al.  The Effects of Serotonin on Local Cerebral Blood Flow , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  T. Cooper,et al.  Pharmacokinetics of chlorimipramine and its demethylated metabolite in blood and brain regions of rats treated acutely and chronically with chlorimipramine. , 1983, The Journal of pharmacology and experimental therapeutics.

[4]  D. Shaw,et al.  Time course of plasma drug levels during once-daily oral administration of clomipramine , 2004, Psychopharmacology.

[5]  R. Jones,et al.  The effects of clomipramine and desmethylclomipramine on the in vitro uptake of radiolabelled 5‐HT and noradrenaline into rat brain cortical slices , 1977, The Journal of pharmacy and pharmacology.

[6]  Suzuki Shigeru,et al.  Changes of serotonin and catecholamines are related to pharmacokinetic alterations of cloimpramine in rat brain , 1991 .

[7]  H. Kao,et al.  [3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor. , 1990, Molecular pharmacology.

[8]  H N Wagner,et al.  Quantitative imaging of neuroreceptors in the living human brain. , 1986, Seminars in nuclear medicine.

[9]  E. Rota Kops,et al.  Performance characteristics of an eight-ring whole body PET scanner. , 1990, Journal of computer assisted tomography.

[10]  Wilhelm Hamkens,et al.  Remote controlled one-step production of 18F labeled butyrophenone neuroleptics exemplified by the synthesis of n.c.a. [18F] N-methylspiperone , 1995 .

[11]  B. Hoffman,et al.  4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]ketanserin labeling of 5-hydroxytryptamine2 (5HT2) receptors in mammalian cells transfected with a rat 5HT2 cDNA: evidence for multiple states and not multiple 5HT2 receptor subtypes. , 1990, Molecular pharmacology.

[12]  D. Brooks,et al.  Evidence for striatal dopamine release during a video game , 1998, Nature.

[13]  J. Hyttel Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs) , 1994, International clinical psychopharmacology.

[14]  J D Brodie,et al.  Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[15]  C. Hiemke,et al.  Steady state concentrations of clomipramine and its major metabolite desmethylclomipramine in rat brain and serum after oral administration of clomipramine , 2000, European Neuropsychopharmacology.

[16]  Gwenn S. Smith,et al.  [18F]Altanserin PET Studies of Serotonin-2A Binding: Examination of Nonspecific Component , 1998 .

[17]  A. Gjedde,et al.  Quantitative functional brain imaging with positron emission tomography , 1998 .

[18]  R. Hotz,et al.  Pharmacokinetics of clomipramine in dogs following single-dose intravenous and oral administration. , 2000, American journal of veterinary research.

[19]  R. Braithwaite,et al.  Techniques for plasma protein binding of demethylchlorimipramine , 1979, Clinical pharmacology and therapeutics.

[20]  D. Charney,et al.  Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent. , 1999, Nuclear medicine and biology.

[21]  M. Laruelle Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  S. Vandel,et al.  Relationship between the plasma concentration of clomipramine and desmethylclomipramine in depressive patients and the clinical response , 2004, European Journal of Clinical Pharmacology.

[23]  M. Hamilton A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[24]  André Luxen,et al.  Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography , 1994, European Journal of Nuclear Medicine.

[25]  M E Phelps,et al.  Neuroreceptor Assay with Positron Emission Tomography: Equilibrium versus Dynamic Approaches , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  H. Müller-Gärtner,et al.  Influence of Motor Activity on Striatal Dopamine Release: A Study Using Iodobenzamide and SPECT , 1999, NeuroImage.

[27]  W. Thormann,et al.  Monitoring of tricyclic antidepressants in human serum and plasma by HPLC: characterization of a simple, laboratory developed method via external quality assessment. , 1998, Journal of pharmaceutical and biomedical analysis.

[28]  C. Lemaire,et al.  Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  J S Fowler,et al.  Kinetic Modeling of Receptor‐Ligand Binding Applied to Positron Emission Tomographic Studies with Neuroleptic Tracers , 1987, Journal of neurochemistry.

[30]  H. Westenberg,et al.  Pharmacokinetics of clomipramine in depressive patients , 1981, Psychiatry Research.

[31]  A. Adamus,et al.  Comparison of the pharmacological actions of desmethylclomipramine and clomipramine , 2004, Psychopharmacology.

[32]  J S Fowler,et al.  Striatal binding of the PET ligand 11C‐raclopride is altered by drugs that modify synaptic dopamine levels , 1993, Synapse.

[33]  D. Thomas,et al.  Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor , 2004, Psychopharmacology.

[34]  A. Alavi,et al.  In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  Donald Sashin,et al.  Test–retest variability of serotonin 5‐HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain , 1998, Synapse.

[36]  W. Koek,et al.  Possible in vivo 5‐HT reuptake blocking properties of 8‐OH‐DPAT assessed by measuring hippocampal extracellular 5‐HT using microdialysis in rats , 1996, British journal of pharmacology.

[37]  Christer Halldin,et al.  Effect of reserpine‐induced depletion of synaptic dopamine on [11C]Raclopride binding to D2‐dopamine receptors in the monkey brain , 1997, Synapse.

[38]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Karl J. Friston,et al.  Statistical parametric maps in functional imaging: A general linear approach , 1994 .

[40]  D. Charney,et al.  Spect imaging of striatal dopamine release after amphetamine challenge in humans: Relationship between subjective effects and dopamine release , 1995, Schizophrenia Research.

[41]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[42]  A. Luxen,et al.  In vivo binding of [18F]altanserin to rat brain 5HT2 receptors: a film and electronic autoradiographic study. , 1997, Nuclear medicine and biology.

[43]  E. Nakashima,et al.  Prediction of Changes in the Clinical Pharmacokinetics of Basic Drugs on the Basis of Octanol‐Water Partition Coefficients , 1997, The Journal of pharmacy and pharmacology.

[44]  J. Feighner,et al.  Selective Serotonin Re-Uptake Inhibitors: The Clinical Use of Citalopram, Fluoxetine, Fluvoxamine, Paroxetine, and Sertraline , 1991 .

[45]  H. Müller-Gärtner,et al.  Encoding and retrieval in declarative learning: a positron emission tomography study , 1998, Behavioural Brain Research.

[46]  P. Seeman,et al.  Dopamine receptors in brain and periphery , 1987, Neurochemistry International.

[47]  J S Fowler,et al.  Amphetamine induced decreases in (18F)‐N‐methylspiroperidol binding in the baboon brain using positron emission tomography (PET) , 1991, Synapse.

[48]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[49]  M. Torrens Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268 , 1990 .